AAIC 2025 Abstract
The Lewy Body Dementia Domain Rating Scale: an update
By Joe PM Kane, Brad F Boeve, Elie Matar, Show 2 more authorsThe Lewy Body Dementia Domain Rating Scale steering group
Abstract
Background: Trials in Lewy body dementia (LBD) rely on scales and measurements created for Alzheimer’s disease and Parkinson’s disease. Industry and regulatory authority stakeholders and LBD triallists have recognised the absence of an LBD‐specific scale as critical unmet need in the drug development pipeline.
